OncoMatch/Clinical Trials/NCT07139366
Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
Is NCT07139366 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments for gastritis.
Treatment: Bismuth · Esomeprazole · Tetracycline · Furazolidone · Saccharomyces Boulardii Oral Powder — This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Prior therapy
Must have received: H. pylori eradication therapy
Patients who had failed H.pylori eradication therapies
Cannot have received: tetracycline or furazolidone antibiotics for H. pylori eradication (tetracycline, furazolidone)
Patients who have previously used tetracycline and furazolidone antibiotics to eradicate infection with H. pylori.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify